Adoptive Immunotherapy

This policy covers adoptive immunotherapy — including autologous or antigen‑specific cytotoxic T‑lymphocyte (CTL) and cytokine‑induced killer (CIK) cell therapies — for certain malignancies such as EBV‑ or CMV‑associated cancers (eg, EBV‑positive nasopharyngeal carcinoma, Hodgkin/non‑Hodgkin lymphoma), renal cell carcinoma, hepatocellular carcinoma and other solid tumors studied. Coverage is limited to indications and regimens proven effective for the specific diagnosis and consistent with FDA labeling or nationally recognized compendia/authoritative sources; many adoptive techniques remain experimental/investigational and actual coverage is determined by the member’s benefit plan.

"Adoptive immunotherapy has been studied for treatment of renal cell carcinoma (RCC)."

Sign up to see full coverage criteria, indications, and limitations.